. Bulk shear viscosities of endogenous and exogenous lung surfactants. Am J Physiol Lung Cell Mol Physiol 282: L277-L284, 2002; 10.1152/ajplung.00199.2001.-Bulk shear viscosities were measured with a cone and plate microviscometer as a function of concentration, shear rate, and temperature for lavaged calf lung surfactant (LS), Exosurf, Infasurf, Survanta, and synthetic lipid mixtures dispersed in normal saline. Viscosity increased with phospholipid concentration for all surfactants, but its magnitude and shear dependence varied widely among the different preparations. Saline dispersions of Exosurf and synthetic phospholipids had low viscosities of only a few centipoise (cp) and exhibited minimal shear dependence. LS, Infasurf, Survanta, and lipid mixtures containing palmitic acid and tripalmitin had larger non-Newtonian viscosities that increased as shear rate decreased. At 35 mg of phospholipid/ml and 37°C, viscosity values were 52.3 cp (Survanta), 31.1 cp (LS), and 25 cp (Infasurf) at a shear rate of 77 s Ϫ1 and 16.9 cp (Survanta), 10.1 cp (LS), and 6.6 cp (Infasurf) at 770 s Ϫ1 . At 25 mg of phospholipid/ml and 37°C, viscosity values at 77 s Ϫ1 were 28.8 cp (Survanta), 4.7 cp (LS), and 12.5 cp (Infasurf). At fixed shear rate, viscosity was substantially decreased at 23°C compared with 37°C for LS and Infasurf but was increased for Survanta. Calcium (5 mM) greatly reduced the viscosity of both Survanta and Infasurf at 37°C. Studies on synthetic mixtures indicated that phospholipid/apoprotein interactions were important in the rheology of lung-derived surfactants and that palmitic acid and tripalmitin contributed to the increased viscosity of Survanta. The viscous behavior of clinical exogenous surfactants potentially influences their delivery and distribution in lungs and varies significantly with composition, concentration, temperature, ionic environment, and physical formulation.
surfactants is of primary importance for in vivo activity, other physical properties such as surface and shear viscosity are also relevant (3, 6, 22) . The majority of exogenous surfactants used in treating RDS are administered clinically as dispersions in 0.15 M NaCl that contain a heterogeneous distribution of phospholipid-rich aggregates. In the case of biologically derived preparations, a small but crucial content of highly active hydrophobic apoproteins that significantly modify phospholipid microstructure and biophysical properties is also present. The rheology of aggregated dispersions and suspensions is complex and can include a strong dependence on shear rate (non-Newtonian viscous behavior), temperature, and concentration (8, 18, 31) . The bulk shear viscosity of exogenous surfactant dispersions is most important during tracheal instillation and transport through the airways to the periphery of the lungs. In particular, viscous properties potentially influence the ability to instill surfactants easily and without obstructing the endotracheal tube as well as the final intrapulmonary distribution achieved by instilled surfactant material.
The present study investigates the bulk shear viscosities of lavaged calf lung surfactant (LS) and several exogenous surfactants approved for clinical use in the United States (Survanta, Infasurf, and Exosurf). Also studied is the viscosity behavior of several synthetic lipid mixtures related compositionally to the lipid components in Survanta and Infasurf. Measurements of shear viscosity are made with a Wells-Brookfield cone and plate microviscometer. Viscosity is examined as a function of surfactant phospholipid concentration and shear rate at both body temperature (37°C) and room temperature (23°C). The influence of calcium, which is known to affect the microstructural aggregation of LS in the aqueous phase, is also studied for its effects on shear viscosity.
MATERIALS AND METHODS
Endogenous lung surfactant. Whole surfactant was obtained by saline lavage of lungs of freshly killed calves (Gold Medal Packing, Rome, NY) as described previously (11, 21, 23) . Lavage was immediately centrifuged at 150 g for 5 min to remove cells, and the supernatant spun at 12,000 g for 30 min to pellet the large aggregate surfactant fraction (designated LS). LS contained ϳ85% phospholipid by weight based on phosphorus assay (1) and dry weight determinations. The protein content of LS was 8.5% relative to phospholipid by the Folin phenol reagent assay (17) modified by the addition of 10% sodium dodecyl sulfate. The content of cholesterol in LS was 4.2% by colorimetric assay (26) . The phospholipid fraction of LS was 82% phosphatidylcholine, 6% phosphatidylglycerol, 5% phosphatidylinositol plus phosphatidylserine, 3% phosphatidylethanolamine, 2% sphingomyelin, and 2% other by thin-layer chromatography with solvent system C of Touchstone et al. (30) . A concentrated stock solution of whole surfactant was diluted with 0.15 M NaCl with or without 5 mM CaCl 2 to desired phospholipid concentrations for viscosity studies. Individual LS samples were studied within 1 wk of formulation.
Clinical exogenous surfactants. Clinical exogenous surfactants were obtained directly from the manufacturers or from the pharmacy at Strong Memorial Hospital (Rochester, NY). Infasurf (ONY, Amherst, NY) and Survanta (Ross Laboratories, Columbus, OH) were suspensions in 0.15 M NaCl at phospholipid concentrations of 35 mg/ml and 25 mg/ml, respectively. Exosurf (Glaxo-Wellcome, Research Triangle Park, NC) was initially in powdered form including salt, and distilled water was added to give a final concentration of 13.5 mg of phospholipid/ml in 0.1 M NaCl. Infasurf and Survanta were studied for viscosity behavior at 25 and 35 mg of phospholipid/ml, whereas Exosurf was studied at 13.5 and 35 mg of phospholipid/ml. For studies at the clinical concentration, aliquots of exogenous surfactant were taken directly from the manufacturer's vials. For studies at other concentrations, Infasurf was diluted with 0.15 M NaCl to 25 mg of phospholipid/ml, Survanta was concentrated to 35 mg/ml by evaporation under nitrogen, and Exosurf was reconstituted with reduced amounts of distilled water. The concentration of NaCl in Survanta and Exosurf was increased above the clinical level at these latter concentrations. Surface activity was not altered by sample preparation. Aliquots of surfactant from the original clinical vials, from concentration-adjusted samples, and after 10 min of viscometric study were unchanged in dynamic surface tension-lowering ability on a pulsating bubble surfactometer (General Transco, Largo, FL). After 2 min of bubble pulsation at 2.5 mg of phospholipid/ml, minimum surface tension values were Ͻ1 mN/m for samples of Infasurf, 3.6 Ϯ 0.5 mN/m for Survanta, and 53.4 Ϯ 1.9 mN/m for Exosurf. Clinical exogenous surfactants were stored refrigerated as recommended, and samples adjusted to nonclinical concentrations were studied within 3-7 days after preparation.
Synthetic lipids. Dipalmitoylphosphatidylcholine (DPPC), egg phosphatidylcholine (egg-PC), egg phosphatidylglycerol (egg-PG), egg phosphatidylethanolamine (egg-PE), soy phosphatidylinositol (soy-PI), and bovine brain sphingomyelin (Sph) were purchased in the highest available purity from Avanti Polar Lipids (Alabaster, AL). Cholesterol, palmitic acid, and tripalmitin were reagent grade from Sigma Chemical (St. Louis, MO). All lipids were used without further purification in viscosity experiments. Dispersions of synthetic lipids for viscosity studies were mixed in chloroform, dried in a tube under nitrogen, and dispersed in 0.15 M NaCl Viscosity measurements. Rheological properties were studied at 23°and 37°C with a Wells-Brookfield cone and plate microviscometer (DV-IIϩ; Brookfield Engineering Laboratories, Stoughton, MA). Shear rate was varied by utilizing one of two different spindles in the viscometer depending on the required torque and shear (CPE-40: 1-1,500 s Ϫ1 ; CPE-51: 1-768 s Ϫ1 ). The spindle and sample cup (CPE-44PSY) were washed with 95% ethanol and nanopure water before each set of viscosity measurements. Spindle position was calibrated to a gap height of 0.0005 inches above the sample cup, and a surfactant dispersion at a standard room temperature volume of 0.5 ml was placed in the sample cup using a syringe. For experiments at body temperature, 10 min was allowed for the sample to equilibrate initially with a circulating water bath. Viscosity measurements for each sample were always made during a single set of experiments proceeding from low to high shear rates to minimize variations from shear-induced aggregate changes. Viscosity values at fixed shear rate were assumed to be at steady state after Ն10 s with no significant change in magnitude. A set of viscosity measurements covering the full range of shear rates at fixed concentration typically required 10-15 min after temperature equilibration. Distilled water and 0.15 M NaCl with and without 5 mM CaCl2 were used as reference standards in viscometer calibration. Newtonian viscosity values for these reference substances were within 1% of each other and known literature values (20).
RESULTS
Shear viscosities of saline suspensions of LS, Survanta, Infasurf, and Exosurf exhibited a wide range of values and shear rate dependence at 37°C (Fig. 1 , Table 1 ). Viscosity values for all surfactant mixtures increased at fixed shear as phospholipid concentration increased. However, viscosity magnitudes for Survanta, LS, and Infasurf were much higher than for Exosurf at fixed concentration and shear rate. Saline dispersions of Survanta, LS, and Infasurf also were non-Newtonian and had increased viscosities at low shear rates compared with high shear rates (Fig. 1) . Of the surfactant preparations studied, Survanta in saline had the highest viscosity values at any given concentration, shear rate, and temperature. At 25 mg of phospholipid/ml and 37°C, the viscosity of Survanta was 28.8 centipoise (cp) at 77 s Ϫ1 and 9.1 cp at 770 s
Ϫ1
( Fig. 1A) . These values were not significantly changed by increasing the NaCl content of Survanta by a factor 1B) . Exosurf had low viscosities near 1 cp at its clinical concentration of 13.5 mg of phospholipid/ml and exhibited only slightly higher viscosities of 1.2-1.4 cp when phospholipid concentration was raised to 35 mg/ml (Table 1) . These viscosity values for Exosurf dispersions are only slightly larger than saline alone, which has a Newtonian viscosity of 0.69 cp at 37°C.
In addition to varying as a function of shear rate and phospholipid concentration, viscosity in surfactant dispersions also depended on temperature (Table 1, Fig.  2 ). Saline suspensions of Survanta and Infasurf displayed marked changes in viscosity at room temperature (23°C) compared with body temperature (37°C). The viscosity of saline suspensions of Exosurf also depended on temperature, but temperature-induced changes were much less pronounced in absolute magnitude than for the lung-derived exogenous surfactants (Table 1 ). In terms of functional dependence on temperature, there were distinct differences between the behavior of Survanta and Infasurf. Viscosity at fixed shear rate was increased in Survanta at room vs. body temperature ( Fig. 2A, Table 1 ). In contrast, Infasurf exhibited substantial reductions in viscosity at fixed shear at room temperature compared with body temperature. The magnitudes of shear viscosity in saline suspensions of Infasurf at room temperature were only a few centipoise across the range of shear rates studied (Fig. 2B, Table 1 ). The viscous behavior of lung surfactant materials in the aqueous phase reflects their component molecular interactions and aggregated lipid-protein microstructures. To help address the influence of dispersion microstructure on rheological behavior, the effects of 5 mM calcium on shear viscosity were examined for Survanta and Infasurf at the concentrations used clinically (25 mg of phospholipid/ml for Survanta and 35 mg of phospholipid/ml for Infasurf; Fig. 3 , Table 1 ). The presence of 5 mM calcium had a striking effect in reducing the magnitude of shear viscosity for both Survanta and Infasurf at 37°C. As discussed later, these calcium-induced viscosity reductions likely reflect, at least in part, increased phospholipid/protein aggregation in the presence of this divalent cation.
A final set of experiments investigated component contributions to shear viscosity behavior. These studies utilized a series of synthetic lipid mixtures (SL1-SL5), which were examined for shear viscosity at 37°C when dispersed in 0.15 M NaCl (Table 2) . SL1 is roughly related to the distribution of lipids in LS and Infasurf, while SL2 is related to the distribution of nonprotein components in Survanta. Mixtures SL3-SL5 are subsets of SL2 lacking either palmitic acid or tripalmitin or both. SL1, containing phospholipids plus 4% cholesterol, exhibited very low viscosity values that varied little with shear rate (Table 2) . SL2, which contained a higher DPPC content than SL1 plus added palmitic acid and tripalmitin as in Survanta, had much larger viscosity values and significant non-Newtonian shear rate dependence. Dispersion by sonication vs. vortexing had a small effect in increasing viscosity at fixed shear for SL1 and a significant effect in increasing viscosity in SL2 (Table 2) . If palmitic acid and tripalmitin were not present, vortexed dispersions of the phospholipids in SL2 had low shear viscosity values similar in magnitude to those found for SL1 (SL3 vs. SL2 in Table 2 ). Palmitic acid (10% by wt) had a greater effect in increasing phospholipid viscosity than tripalmitin (4% by wt) when the two compounds were present separately (SL4 and SL5 vs. SL3 in Table 2 ). However, the greatest increases in phospholipid viscosity occurred when these levels of palmitic acid and tripalmitin were present together (SL2 vs. SL4 and SL5 in Table 2 ). 
DISCUSSION
This study examined the magnitude and shear rate dependence of viscosity in saline suspensions of LS, clinical exogenous surfactants (Exosurf, Infasurf, and Survanta), and several synthetic lipid mixtures dispersed in isotonic saline. Because of their complex lipid and protein composition and heterogeneous aggregated microstructure in the aqueous phase, dispersed lung surfactant materials can display complex rheological behavior. Our prior work has shown that lavaged LS and its chloroform:methanol extract exhibit non-Newtonian viscosity characteristics that depend strongly on concentration and temperature (16) . Shear-dependent, concentration-dependent behavior was also found in the present study for Survanta and Infasurf, two clinical exogenous surfactants that contain a substantial content of lung-derived surface active material. In contrast, the synthetic protein-free exogenous surfactant Exosurf had much lower shear viscosity values and relatively little non-Newtonian shear dependence. Exosurf, however, is no longer widely used in clinical surfactant replacement therapy because its surface and physiological activity is lower than that of lung-derived exogenous surfactants (10, 13-15, 25, 32) .
Saline dispersions of all of the lung-derived exogenous surfactants studied had bulk shear viscosities at body temperatures that were much larger than saline alone at concentrations relevant for clinical use (Fig. 1 , Table 1 ). The non-Newtonian viscous behavior of endogenous LS and related hydrophobic organic solvent extracts has been shown previously to become more pronounced as concentration increases (16) . Suspensions of whole and extracted calf LS in isotonic saline have viscosities of only 1-1.3 cp at concentrations of 5 and 10 mg of phospholipid/ml, relatively close to saline alone (0.69 cp at 37°C) (16) . In the present study, shear viscosity increased with phospholipid concentration for Survanta, Infasurf, and LS, but significant quantitative differences were found between these surfactant preparations. The viscosity of Survanta was much larger at fixed concentration and shear rate than either LS or Infasurf. Infasurf at its clinical concentration of 35 mg of phospholipid/ml had a smaller viscosity than Survanta at its lower clinical concentration of 25 mg of phospholipid/ml (Fig. 1) . At the same concentration, viscosity values for Survanta at fixed shear were about twice those of Infasurf. Lavaged LS had slightly higher viscosities at fixed shear than Infasurf at 35 mg of phospholipid/ml but lower viscosities at 25 mg of phospholipid/ml.
Viscous behavior in lung surfactant suspensions reflects their aggregated phospholipid-apoprotein microstructures that differentiate them from simple aqueous solutions. LS, Infasurf, and Survanta all contain a broad mix of phospholipid components that make up a majority of their content by weight. Phospholipids in water are known to aggregate to form bilayers, lamellae, vesicular liposomes, and other less regular forms (for review, see Refs. 4, 7, and 28). Moreover, in lungderived surfactant preparations, the structure and properties of microstructural aggregates are strongly influenced by surfactant apoproteins. Alveolar surfactant contains three biophysically active surfactant proteins: SP-A, SP-B, and SP-C. The microstructure of whole endogenous surfactant in saline in the presence of calcium contains tubular myelin along with a spectrum of other large and small aggregate forms (2, 19, 23, 24, 34) . The distinctively ordered three-dimensional tubular myelin network of intersecting phospholipid bilayers is not present in Infasurf and Survanta because SP-A is eliminated during organic solvent extraction (23, 29, 33) . However, the microstructure of these extracts also contains a heterogeneous distribution of phospholipid-rich aggregates with incorporated hydrophobic apoproteins (23, 29) . The present study did not attempt to quantitate aggregate structure or size distribution in exogenous surfactants, and this needs to be addressed in future research. Our studies on synthetic lipid mixtures suggest that interactions between surfactant apoproteins and phospholipids contribute significantly to shear viscosity in lung-derived surfactant preparations, particularly LS and Infasurf. A mixture of synthetic phospholipids plus 4% cholesterol that roughly approximated the lipid composition of LS and Infasurf had very low shear viscosities at 37°C (SL1, Table 2 ). Synthetic phospholipids with a higher DPPC content also exhibited very low shear viscosity values (SL3, Table 2 ), as did protein-free Exosurf (Table 1) . This latter surfactant contains DPPC as its major component, but tyloxapol and hexadecanol are also present to potentially impact viscous behavior. The very different shear viscosities of phospholipid mixtures compared with lung-derived surfactants indicates the rheological importance of apoprotein-related interactions. Palmitic acid and tripalmitin, which are additives in Survanta, were also found to be associated with increased shear viscosity in mixtures with phospholipids. Palmitic acid (10% by wt) had a greater affect on viscosity than tripalmitin (4% by wt) when added separately to phospholipids (SL4 vs. SL5, Table 2 ). However, viscosity was increased most substantially when both compounds were present (SL2, Table 2 ). The much higher viscosity of Survanta relative to LS or Infasurf likely includes contributions from palmitic acid and tripalmitin. Fatty chain similarity is an important factor in phospholipid molecular interactions (7, 22) , and the C16:0 chains in palmitic acid and tripalmitin can interact preferentially with DPPC and other saturated species. The smaller palmitic acid molecule may also penetrate multilamellar lipid aggregates and affect packing to promote interactions with tripalmitin. Specific changes in the structure, packing, or deformability of phospholipid aggregates associated with palmitic acid, tripalmitin, or hydrophobic surfactant apoproteins were not assessed in our experiments.
The present study demonstrated a strong temperature dependence in the rheological behavior of LS, Survanta, and Infasurf. This is consistent with prior work showing that temperature can affect the viscosity of whole and extracted bovine LS (16) . Simple aqueous solutions generally decrease in viscosity as temperature increases. Lavaged LS and Infasurf display the interesting behavior that at fixed concentration and shear rate, viscosity is lower at room temperature (23°C) than at body temperature (37°C; Table 1 , Fig. 2 ). In contrast, the viscosities of Survanta and Exosurf were found to be higher at room vs. body temperature ( Table 1, Fig. 2 ). Temperature dependence in lung surfactant viscosity is generated not only by thermodynamic factors operative in simple solutions but also by the complex biophysics of phospholipids and apoproteins. Phospholipids exhibit temperature-dependent fluidity and phase behavior (7, 22, 27) , which is modified further by interactions with apoproteins in lung surfactants. LS, Infasurf, and Survanta contain a broad mix of phospholipids that as pure compounds are in the rigid gel phase or the more fluid liquid crystal phase at room or body temperature, depending on their headgroups and chains. DPPC, the single most prevalent phospholipid component of endogenous surfactant, has a gel to liquid crystal transition temperature near 41°C. However, the phase behavior of lung-derived surfactants depends on the miscibility, cooperativity, and interactions of multiple lipid and protein components and is not fully understood at the molecular level.
The shear viscosities of both Infasurf and Survanta were strikingly reduced by the presence of calcium ( Table 1, Fig. 3 ). Calcium has previously been shown to decrease the viscosity of calf lung surfactant extract as well as to reduce the viscosity of whole surfactant at low (but not high) shear rates (16) . One major action of calcium on aqueous suspensions of endogenous lung surfactant is to increase protein-mediated phospholipid aggregation (2, 5, 9, 12, 19, 22) . At fixed shear rate and concentration, increased aggregation leads to a reduction in the total surface area under shear, tending to reduce resistance to flow. Additional factors including lipid-protein interactions, phospholipid phase properties, and aggregate deformability and fluidity also influence the shear viscosity of lung surfactants in water as discussed earlier. Viscosity is also dependent on physical dispersion methodology, which is known to affect the aqueous phase microstructure of LS and phospholipids (4, 7, 23, 28) . Changes in dispersion methodology were found here to affect viscosity in lipid mixtures (sonicated vs. vortexed SL1 and SL2 in Table 2 ). The ability to impact viscosity by varying ionic environment, temperature, or processing methodology may be useful in modifying viscous properties in current or future exogenous surfactant preparations. The practical utility of any manipulation for reducing shear viscosity, however, will obviously depend on not compromising surface properties that are of primary importance for surfactant activity.
Shear rates encountered by exogenous surfactants during instillation and spreading through the pulmonary airways in patients have not been measured, and a range of values extending below the lower limit examined here (70 s Ϫ1 ) is possible. The viscosities of saline dispersions of the lung-derived surfactants in our study all increased as shear rate decreased at phospholipid concentrations of 25 and 35 mg/ml. In terms of clinical surfactant delivery, our results imply that viscous resistance during intratracheal instillation will vary significantly with temperature and surfactant preparation. Equilibration of instilled exogenous surfactant to body temperature necessarily occurs during distribution in the pulmonary airways. However, the temperature of instilled material can be varied to reduce viscous forces. Viscosity values for Infasurf were reduced to only a few centipoise at room temperature (23°C; Table 1, Fig. 2 ), suggesting that warming refrigerated vials of this exogenous surfactant to room rather than body temperature for clinical instillation would be best. Survanta, however, had even larger viscosity values at room temperature than at body temperature (Table 1, Fig. 2 ), indicating that warming this surfactant to body temperature for instillation would be preferable.
In summary, this study has shown that saline suspensions of lavaged calf LS and several exogenous surfactants based in whole or in part on lung-derived surface active material have non-Newtonian concentration-dependent viscosities an order of magnitude or more larger than saline at low shear rates. Of the clinical surfactants studied, Survanta had the highest viscosity and Exosurf the smallest. At 37°C and low shear rate, the viscosity of Survanta in saline at 25 or 35 mg of phospholipid/ml was over twice as large as the viscosity of Infasurf at equivalent concentration. The viscosity of Survanta at fixed shear and concentration also exceeded that of whole LS by a similar amount. The viscosities of LS and Infasurf were decreased at room vs. body temperature while that of Survanta was increased. Calcium (5 mM) significantly reduced the viscosities of Survanta and Infasurf across a range of shear rates. Studies with model lipid mixtures suggested that interactions between surfactant apoproteins and lipids are important contributors to viscous behavior and that the presence of palmitic acid and tripalmitin in mixtures with phospholipids is associated with increased shear viscosity.
